in Halifax, Nova Scotia. This is your chance to learn about all aspects of GBS, CIDP and its variants from initial diagnosis to treatment and rehabilitation. Be sure to check our
page for upcoming chapter meetings in a city near you.
CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
During the month of May, in an effort to increase awareness in each of our communities, we encourage everyone to organize activities that highlight GBS, CIDP and their variants. Throughout the world, individuals and groups have organized fundraising events such as walks, runs, bake sales, fashion shows, cocktail receptions, and art shows.